Elevance Health (ELV) Soars as Investors Gain Confidence in Profitability

Elevance Health (ELV) Soars as Investors Gain Confidence in Profitability

Tue, September 1, 2026 at 5:19 PM GMT+3 3 min read

First Eagle Investment Management, an investment management company, released its Q2 2026 investor update for "First Eagle Global Fund". The letter can be downloaded here. Easing tensions in the Middle East led to a strong rally in risk markets in Q2. The S&P 500 Index rose 15.2%, while the MSCI EAFE Index gained 10.8%. Growth stocks outperformed, with the MSCI World Growth Index significantly exceeding value returns. A notable shift in U.S. interest rate expectations followed Kevin Warsh's appointment as chair of the Federal Open Market Committee, pushing Treasury yields higher and strengthening the dollar. Despite the optimistic market environment, concerns about fiscal constraints and limited policy flexibility remain. Tighter credit spreads and elevated equity valuations reflect strong demand for financial assets, with household wealth in equities at a post-WWII high. Earnings expectations are buoyant, driven by AI infrastructure developments. Against this backdrop, Global Fund A Shares returned 2.86% in Q2 2026, with emerging markets and developed Europe as the primary contributors. Developed Asia (excluding Japan) was the only detractor, and Japan lagged. Information technology and financials led among equity sectors, while materials and energy detracted. The fund underperformed relative to the MSCI World Index during this period. Also, check the fund's top five holdings to see its best picks in 2026.

In its second-quarter 2026 investor letter, First Eagle Global Fund highlighted Elevance Health, Inc. (NYSE:ELV) as a notable contributor. Elevance Health, Inc. (NYSE:ELV) is a US-based health benefits company. On August 31, 2026, Elevance Health, Inc. (NYSE:ELV) closed at $392.54 per share. Over the past month, Elevance Health, Inc. (NYSE:ELV) reported 3.85%, but its shares are up 21.78% over the past year. Elevance Health, Inc. (NYSE:ELV) has a market capitalization of $85.13 billion, and its stock has traded within a 52-week range of $274.84 to $436.24.

First Eagle Global Fund stated the following regarding Elevance Health, Inc. (NYSE:ELV) in its Q2 2026 investor letter:

"Shares of Elevance Health, Inc. (NYSE:ELV), the health insurer and healthcare-services provider formerly known as Anthem, rallied during the quarter as margins expanded—after a protracted decline—due to declining medical costs, stronger pricing and increased utilization with higher premiums."

Elevance Health, Inc. (NYSE:ELV) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 84 hedge fund portfolios held Elevance Health, Inc. (NYSE:ELV) at the end of the second quarter, which was 87 in the previous quarter. While we acknowledge the potential of Elevance Health, Inc. (NYSE:ELV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we discussed Elevance Health, Inc. (NYSE:ELV) and shared Sound Shore Fund's views on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. This article is originally published at Insider Monkey.